Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with a type of skin lymphoma called Cutaneous T-Cell Lymphoma (CTCL), confirmed using specific medical guidelines from 2017
- You are 18 years of age or older
- You received your first full-body (systemic) treatment for at least 3 months, and that treatment started sometime between January 1, 2016 and December 31, 2023
- Your full medical records are available and contain all the details this study requires
- You are willing and able to sign a consent form agreeing to take part in the study
Who may not be able to join:
- You do not meet all of the requirements listed above
- You are not willing to sign the consent form agreeing to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pietro Quaglino, MD, SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino
Phone: +390131033153
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.